Nucleos Biotech is proud to announce its participation in the Nucleate Germany Activator 2026 program, one of Europe's most dynamic platforms for early-stage biotech development. On March 12, 2026, Dr. Abraham Chokri, co-founder and scientific lead of Nucelos Biotech, was invited as an independent expert reviewer for the program's Application and Market Risk Workshop — a milestone that reflects our growing role as a strategic voice at the intersection of European life sciences and Gulf investment networks.
Expert Mentorship in Action: Supporting the Next Generation of Biotech Innovators
For this workshop, Dr. Chokri was assigned to work with Plantman, a compelling early-stage preclinical biotech developing plant-derived protein therapies for Huntington's Disease and other neurodegenerative indications. Over the course of the session, he provided structured expert feedback spanning competitive positioning, investment readiness, market risk assessment, and commercialization pathways — delivering the kind of frank, actionable guidance that early-stage teams need as they prepare for their first institutional funding rounds.
Following the workshop, Dr. Chokri went beyond the session itself, providing the Plantman team with three dedicated deliverables: a VC and Strategic Advisory Feedback Report covering eight dimensions of investment readiness and four prioritized recommendations, a detailed Huntington's Disease Competitive Landscape analysis contextualizing Plantman's mechanism relative to programs such as AMT-130, tominersen, and WVE-003, and a structured Session Memo capturing key discussion points and agreed next steps.
This engagement also opened a natural conversation about what Nucleos Biotech can offer Plantman as they move toward their seed round. As a UAE-based biotechnology platform headquartered in Masdar City, Abu Dhabi, Nucelos is uniquely positioned to connect European preclinical orphan disease programs with Gulf sovereign wealth funds, family offices, and GCC-based venture capital networks that are actively seeking exposure to this space. We are in active discussion with the Plantman team about supporting their GCC market entry strategy and facilitating the right introductions at the right moment.
More broadly, Nucleos Biotech is delighted to formally join the Nucleate Germany ecosystem as a biotech expert and mentor for spin-offs and startups operating in the fields of biotherapy and advanced therapies. We believe that the most transformative scientific ideas deserve not only rigorous expert challenge, but access to the capital and strategic networks that can carry them forward — across geographies, and across funding cycles.
Our mission at Nucleos has always been to serve as a catalyst: connecting the best of European biotech innovation with the ambition and capital of the GCC region. This partnership with Nucleate Germany is a meaningful step in that direction, and one we intend to build on.
We look forward to many more collaborations ahead.